Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss

Lerner,Lorena; Gyuris,Jeno; Nicoletti,Richard; Gifford,James; Krieger,Brian; Jatoi,Aminah

doi:10.3892/ol.2016.5183

November-2016 Volume 12 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2016 Volume 12 Issue 5

Full Size Image

Article

Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss

Authors:
- Lorena Lerner
- Jeno Gyuris
- Richard Nicoletti
- James Gifford
- Brian Krieger
- Aminah Jatoi
View Affiliations / Copyright

Affiliations: AVEO Pharmaceuticals, Cambridge, MA 02142, USA, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Pages: 4219-4223
|
Published online on: September 23, 2016

https://doi.org/10.3892/ol.2016.5183
Expand metrics +

Abstract

Growth differentiating factor-15 (GDF-15), also known as macrophage inhibiting factor‑1, is a member of the transforming growth factor‑β superfamily, which has been implicated in cancer‑associated weight loss. The present study investigated the association between cancer‑associated weight loss and plasma GDF-15 concentration, as well as other biomarkers, in patients with metastatic lung or exocrine pancreatic cancer. A total of 218 patients were enrolled over a 1-year period. The patient cohort included 152 patients with incurable lung cancer and 66 patients with incurable pancreatic cancer. Of the 218 patients, 98 (45%) reported >5% weight loss, 62 (28%) reported ≤5% weight loss and 58 (27%) reported no weight loss in the 6 months prior to diagnosis. In lung cancer patients, higher circulating GDF‑15 levels were significantly associated with weight loss; lung cancer patients who reported >5% weight loss (n=56) were found to exhibit twice the circulating concentration of GDF‑15 compared with those that exhibited no weight loss (n=48) (P<0.0001). Additional mediators, including Activin A, interleukin (IL)‑12, vascular endothelial growth factor A, IL‑1 receptor α, eotaxin and platelet derived growth factor‑BB, were also associated with weight loss; however, the associations were not as strong. In pancreatic cancer patients, no association between GDF‑15 levels and weight loss was identified. However, higher circulating GDF‑15 levels were consistently associated with poor survival in univariate [hazard ratio (HR), 1.13; 95% confidence interval (CI), 1.02‑1.23; P=0.016] and multivariate [HR, 1.1; 95% CI, 1.02-1.24; P=0.03] analysis, respectively. Thus, GDF‑15 requires further study as a biomarker and potential therapeutic target in cancer‑associated weight loss, particularly in lung cancer patients.

View Figures

View References

1	Del Fabbro E, Dalal S and Bruera E: Symptom control in palliative care - Part II: Cachexia/anorexia and fatigue. J Palliat Med. 9:409–421. 2006. View Article : Google Scholar : PubMed/NCBI
2	von Haelhling S and Anker SD: Treatment of cachexia: An overview of recent developments. Int J Cardiol. 184:736–742. 2015. View Article : Google Scholar : PubMed/NCBI
3	Penet MF and Bhujwalla ZM: Cancer cachexia, recent advances, and future directions. Cancer J. 21:117–122. 2015. View Article : Google Scholar : PubMed/NCBI
4	Morley JE, Thomas DR and Wilson MM: Cachexia: Pathophysiology and clinical relevance. Am J Clin Nutr. 83:735–743. 2006.PubMed/NCBI
5	Kim A and Nemeth E: New insights into iron regulation and erythropoiesis. Current Opin Hematol. 22:199–205. 2015. View Article : Google Scholar
6	Corre J, Hébraud B and Bourin P: Concise review: Growth differentiating factor 15 in pathology: A clinical role? Stem Cells Transl Med. 2:946–952. 2013. View Article : Google Scholar : PubMed/NCBI
7	Tsai VW, Macia L, Johnen H, Kuffner T, Manadhar R, Jørgensen SB, Lee-Ng KK, Zhang HP, Wu L, Marquis CP, et al: TGF-b superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator. PLoS One. 8:e551742013. View Article : Google Scholar : PubMed/NCBI
8	Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, Wu L, Pankhurst G, Jiang L, Junankar S, et al: Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med. 13:1333–1340. 2007. View Article : Google Scholar : PubMed/NCBI
9	Vigano A, Lerner L, Tao N, et al: From bench to bedside: are cytokines still relevant biomarkers for staging cancer cachexia? Proceedings of the 104^th Annual Meeting of the AACR, 2013. Washington, DC. Philadelphia. abstract 4650. 2013;
10	Lerner L, Hayes T, Tao N, et al: Plasma growth differentiating factor-15 (GDF-15) and other inflammatory markers are associated with weight loss and poor prognosis in cancer patients. Proceedings of the 104th Annual Meeting of the AACR. 2013 Apr 6-10; Washington, DC. Philadelphia. abstract 3504; 2013.
11	Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12:489–495. 2011. View Article : Google Scholar : PubMed/NCBI
12	Lerner L, Tao N, Krieger B, et al: Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody. Proceedings of the 106th Annual Meeting of the AACR. 2015 Apr 18-22; Philadelphia, Pennsylvania. abstract 1115; 2015.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss

This article is mentioned in:

Abstract

Related Articles